Lexicon Pharmaceuticals LXRX Business Segments — Cost of Sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's business segments — cost of sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's business segments — cost of sales?
- Lexicon Pharmaceuticals (LXRX) reported business segments — cost of sales of $108K in Q1 2026.
- How has Lexicon Pharmaceuticals's business segments — cost of sales changed year-over-year?
- Lexicon Pharmaceuticals's business segments — cost of sales increased by 260.0% year-over-year, from $30K to $108K.
- What does business segments — cost of sales mean?
- The direct costs attributable to the production and delivery of goods or services sold by the business segment. This includes raw materials, direct labor, and manufacturing overhead directly linked to revenue generation. Monitoring this metric helps assess the segment's gross margin efficiency and production cost control.